Protagonist Enters Obesity Fray With Triple-G Pill, Eyeing 2026 Clinical Start

By /

With PN-477, Protagonist is directly going up against Eli Lilly, which is advancing retatrutide, also a triple-G agonist, in a Phase II trial.

Scroll to Top